Macro Finance
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
CNBC Business·July 21, 2026·1 min read
Novo Nordisk filed a lawsuit against Eli Lilly, alleging the company ran deceptive GLP-1 drug advertisements. Novo asked the court to permanently stop the ads and require corrective advertising. The legal action escalates competition in the weight-loss and diabetes drug market, where both companies market popular GLP-1 receptor agonist medications.
Read at CNBC BusinessDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.